

NCT ID	NCT05714553
Title	NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase	Phase 1, Phase 2
Date Added	2023-02-06
Location	United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Terminated
Drugs	Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
Tags	MSI-H/ MMRd
NCT ID	NCT04332653
Title	NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2020-04-03
Location	Florida, United States Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Completed
Drugs	NT-I7, Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT04041310
Title	Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2019-08-01
Location	California, United States Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd
NCT ID	NCT05213195
Title	NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
Phase	Phase 1
Date Added	2022-01-28
Location	China

Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	NKG2D CAR-NK
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04575922
Title	Nivolumab+Ipilimumab+RT in MSS mCRC
Phase	Phase 2
Date Added	2020-10-05
Location	Massachusetts, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab
Tags	MSS/ MMRp
NCT ID	NCT03104439
Title	Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
Phase	Phase 2
Date Added	2017-04-07
Location	Massachusetts, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03983993
Title	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2019-06-12
Location	Georgia, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Niraparib, panitumumab, Vectibix, Zejula
Tags	MSS/ MMRp
NCT ID	NCT04940546
Title	Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients
Phase	Phase 1, Phase 2
Date Added	2021-06-25
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, capecitabine, oxaliplatin, Sintilimab
Tags	MSS/ MMRp
NCT ID	NCT05798533

Title	Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
Phase	Phase 1
Date Added	2023-04-04
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cyclophosphamide, Fludarabine, Interleukin-2
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT05783089
Title	MSLN-targeted CAR-T Cells in Solid Tumors.
Phase	Phase 1
Date Added	2023-03-24
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp